Primorus Investments - Result of Meeting and Share Consolidation
RNS Number : 1065Q
Primorus Investments PLC
16 October 2019
 

Primorus Investments plc

("Primorus" or the "Company")

Result of General Meeting

Primorus Investments plc (AIM: PRIM, NEX: PRIM) announces that at the General Meeting held today, the resolution put to shareholders regarding the Share Capital Consolidation (the "Consolidation") as set out in the Circular sent to shareholders on 26 September 2019 was duly passed.

The terms of the Consolidation are that every 20 Existing Ordinary Shares of 0.01 pence each in the capital of the Company will be consolidated into 1 New Ordinary Share of 0.2 pence each in the capital of the Company. The record date for the Consolidation is 21 October 2019 and the New Ordinary Shares will be admitted to trading on AIM and the NEX Exchange on 22 October 2019 ("Admission"). At that time, on Admission, the Company will have 139,830,968 New Ordinary Share in issue. The total number of voting rights in the Company after the Consolidation will therefore be 139,830,968, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to there interest in, the share capital of the Company under the Disclosure and Transparency Rules.

Upon Admission, the New Ordinary Shares will trade under ISIN: GB00BKTCLJ25 and SEDOL: BKTCLJ2 with TIDM: PRIM

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

For further information, please contact:

Primorus Investments plc:     

+44 (0) 20 7440 0640

Alastair Clayton




Nominated Adviser:

+44 (0) 20 7213 0880

Cairn Financial Advisers LLP


James Caithie / Sandy Jamieson




Broker:

+44 (0) 20 3657 0050

Turner Pope Investments (TPI)


Zoe Alexander / Andy Thacker


 


This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMUNAARKWARAAA ]]>